Berton Giachetti, Pier Paolo M.
Curigliano, Giuseppe http://orcid.org/0000-0003-1781-2518
Article History
First Online: 19 December 2023
Competing interests
: G.C. has received honoraria for speaker’s engagement from Bristol Myers Squibb (BMS), Celltrion, Foundation Medicine, Lilly, MSD, Novartis, Pfizer, NanoString, Roche, Samsung and Seattle Genetics; for consultancy roles from NanoString, Roche and Seattle Genetics; for participating in advisory boards from Celltrion, Foundation Medicine, Lilly, Mylan, Pfizer, Roche and Samsung; for writing engagement from BMS and Novartis; and for participation in the Ellipsis Scientific Affairs Group. G.C. also reports institutional research funding for conducting phase I and II clinical trials from AbbVie, AstraZeneca, Bayer, BMS, Celgene, Janssen-Cilag, Medimmune, Medivation, Merck Serono, MSD, Novartis, Orion, Pfizer, Philogen, Roche, Sanofi, Seattle Genetics, Servier and Tesaro. G.C. also declares non-financial interests with the Italian National Health Council as Advisor for Ministry of Health, the European Society for Medical Oncology (ESMO) as Clinical Practice Guidelines Chair, Europa Donna as Member of the Scientific Council, the European Society of Breast Cancer Specialists (EUSOMA) as a member of the Advisory Council and Fondazione Beretta. All of these competing interests were outside the submitted work. P.P.M.B.G. declares no competing interests.